Suzanne Cheng

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

Grant A. McArthur, Paul B. Chapman, Caroline Robert et al. · The Lancet Oncology · 2014 · 978 citations

Medicine, Oncology, Pharmacology +13

A Multilocus Genotyping Assay for Candidate Markers of Cardiovascular Disease Risk

Suzanne Cheng, Michael Grow, Céline Pallaud et al. · Genome Research · 1999 · 207 citations · Full text

Medicine, Genetics, Molecular Genetics +13

Long PCR

Suzanne Cheng, Sheng-Yung Chang, Patti E. Gravitt et al. · Nature · 1994 · 175 citations

Gene interactions and stroke risk in children with sickle cell anemia

Carolyn Hoppe, William Klitz, Suzanne Cheng et al. · Blood · 2003 · 174 citations · Full text

Medicine, Genetics, Hematology +15

Analytical Performance of a Real-time PCR-based Assay for V600 Mutations in the BRAF Gene, Used as the Companion Diagnostic Test for the Novel BRAF Inhibitor Vemurafenib in Metastatic Melanoma

Harkanwal Halait, Kelli DeMartin, Sweta Shah et al. · Diagnostic Molecular Pathology · 2012 · 145 citations

Medicine, Molecular Biology, Oncology +17